Clinical trial
Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and…
NCT00399711 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00399711 |
|---|---|
| Title | Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes |
| Official title | Repaglinide and Metformin Combination Tablet (NN4440) in a TID Regimen Compared to a BID Regimen and BID Avandamet in Subjects With Type 2 Diabetes: A Twenty-Six Week, Open-Label, Multicenter, Randomized, Parallel Group Trial to Investigate Efficacy and Safety |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes, Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | repaglinide and metformin combination tablet, rosiglitazone and metformin combination tablet |
| Enrollment | 560 |
| Start date | Nov 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Nov 15, 2006 |
| Last update posted | Feb 10, 2017 |
| Countries | Puerto Rico, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: